✦ LIBER ✦

Three-year follow-up of galantamine therapy for Alzheimer's disease: Efficacy and tolerability in open-label extension studies

✍ Scribed by G. Wilcock; L. Truyen

Book ID: 119576378
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 254 KB
Volume: 12
Category: Article
ISSN: 0924-977X
DOI: 10.1016/s0924-977x(02)80622-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A 2-year open-label study of galantamine

A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong

✍ L. W. Chu; P. Y. Yik; W. Mok; C. P. Chung 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 591 KB

A 6-month open-label study of the effect

A 6-month open-label study of the effectiveness and tolerability of galantamine in patients with Alzheimer's disease

✍ C.E. Patterson; A.P. Passmore; V.L.S. Crawford 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

Safety Profile and Tolerability of Up to

Safety Profile and Tolerability of Up to 1 Year of Pregabalin Treatment in 3 Open-Label Extension Studies in Patients With Fibromyalgia

✍ Lesley M. Arnold; Birol Emir; T. Kevin Murphy; Bernhardt G. Zeiher; Lynne Pauer; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 429 KB

Efficacy and safety of donepezil over 3

Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease

✍ A. Burns; S. Gauthier; C. Perdomo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 2 views

## Abstract ## Objective This 132‐week, open‐label extension study assessed the long‐term efficacy and safety of donepezil in 579 patients with mild to moderate Alzheimer's disease (AD) who had previously participated in a 24‐week double‐blind study of 5 or 10 mg/day donepezil __vs__ placebo. ##

P.5.c.001 A 3-year open-label, follow-up

P.5.c.001 A 3-year open-label, follow-up study to evaluate the efficacy and tolerability of sarizotan in Parkinson's disease patients with treatment-associated dyskinesia

✍ T. Müller 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Safety and efficacy of maintenance infli

Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extension

✍ Hyams, Jeffrey; Walters, Thomas D.; Crandall, Wallace; Kugathasan, Subra; Griffi 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 296 KB